Neurological drug screens

Details Neurological drug screens Neurological drug screens

1998-01-15

2000-07-11

Kunz, Gary L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

435 71, 435 72, 435 721, 514 12, 530350, A61K 3802, A61K 3817, C07K 200, C07K 14435

Patent

active

060873264

ABSTRACT:
Compositions for identifying lead compounds for pharmacological agents useful in the diagnosis or treatment of neurological disease or injury include mixtures comprising an isolated netrin and an isolated natural netrin receptor such as "Deleted in Colorectal Carcinoma" (DCC) and neogenin. The general methods involve incubating a mixture of an isolated mammalian netrin, an isolated natural mammalian netrin receptor, and a candidate pharmacological agent, and determining if the presence of the agent modulates the binding of the netrin to the receptor.

REFERENCES:
Serafini et al., Cell, vol. 78, pp. 409-424, 1994.
Vielmetter et al., J. Cell Bio., vol. 127, pp. 2009-2020, 1994.

Affiliated with

Also associated with

Rating

Neurological drug screens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neurological drug screens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurological drug screens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-542417